Heron Therapeutics | HRTX - 流动负债



金融业
股票价格
USD
资产
USD 252.26M
现金及等价物
USD 20.72M
销售成本
USD 11.12M
流动资产
USD 229.85M
流动负债
USD 92.15M
债务
USD 149.65M
股息收益率
0
EBIT
USD 38K
EBITDA
USD -3.88M
员工
126
EPS每股收益
USD -0.02
股本和储备
USD 6.91M
销售毛利
USD 29.47M
债务利息支出
USD 600K
利息收入
USD 433K
贷款资金
USD 140.64M
市值
USD 49.9M
净收入
USD -2.95M
营业费用
USD 40.55M
营业利润
USD 38K
普通股股本
USD 188.31M
税前利润
USD -2.95M
销售收入
USD 40.59M
销售和管理费用
USD 23.74M
股票
USD 54.57M
贸易债权人
USD 11.64M
应收帐款人
USD 89.59M


流动负债 更改 日
ALKERMES USD 662.09M 62.59M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Amarin USD 164.2M 15.45M 2026-06
ANI Pharmaceuticals USD 283.65M 44.14M 2026-06
Anika Therapeutics USD 22.15M 1.18M 2026-06
Arrowhead Research USD 283.35M 11.87M 2026-06
Eisai JPY 393.64B 53.39B 2026-06
Emergent BioSolutions USD 651.3M 12.7M 2023-12
GlaxoSmithKline GBP 21.53B 895M 2026-06
Heron Therapeutics USD 92.14M 1.63M 2026-06
Insmed USD 438.74M 77.74M 2026-06
Ligand Pharmaceuticals USD 46.74M 6.07M 2026-06
Merck USD 27.73B 786M 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Omeros USD 85.5M 2.28M 2025-06
Pacira USD 122.01M 13.22M 2026-06
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
Veracyte USD 62.74M 6.62M 2026-06
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06